‘BIGGEST IPOS IN HISTORY’: OpenAI, SpaceX could rewrite Wall Street

Key Concepts

• IPO (Initial Public Offering): The process of offering shares of a private corporation to the public in a new stock issuance.
• CAPEX (Capital Expenditure): Funds used by a company to acquire, upgrade, and maintain physical assets or infrastructure.
• TAM (Total Addressable Market): The overall revenue opportunity available for a product or service.
• GLP-1 Agonists: A class of medications (e.g., Eli Lilly’s next-gen drug) used for diabetes and weight management that mimic hormones to regulate appetite.
• Bariatric Surgery: Surgical procedures performed on the stomach or intestines to induce weight loss.
• Retail Investing: Individual investors buying and selling securities for their personal accounts, often via platforms like Robinhood or Fidelity.

---

1. The SpaceX vs. OpenAI IPO Showdown

The discussion highlights a high-stakes rivalry between Elon Musk’s SpaceX and Sam Altman’s OpenAI, both of which are reportedly preparing for massive IPOs.

• SpaceX: Targeting an $80 billion raise with a valuation exceeding $1.5 trillion. The company plans to allow retail investors to participate in the IPO through platforms like Schwab, Fidelity, and Robinhood.
• OpenAI: Reports suggest a potential IPO filing as early as tomorrow, with a target to go public by September.
• Market Impact: If these valuations hold, SpaceX could become the 6th largest company by market cap, and OpenAI could rank 14th.
• Capital Allocation: Dagen notes that SpaceX is heavily pivoting toward AI, spending $20 billion in CAPEX on AI infrastructure—more than it spends on rockets and connectivity combined.

2. The Rise of Anthropic and "Claude Code"

A significant portion of the discussion focuses on Anthropic, which is also expected to go public in the fall with a valuation potentially exceeding $1 trillion.

• Performance: Anthropic’s "Claude Code" is highlighted as a transformative product that has forced competitors like Google and OpenAI to adapt.
• Financials: The company is reportedly doubling its revenue and is on track to achieve an operating profit in the current quarter, with revenue nearing $11 billion.
• Industry Impact: The software has revolutionized software development across sectors including automotive and finance, where hedge funds use it to automate trading strategies.

3. Market Skepticism and Economic Philosophy

The panel debated the validity of these massive valuations:

• The "Duck" Argument: Jackie expressed concern that these companies lack the long-term profit track records of established giants like Apple, Microsoft, and NVIDIA. She questioned the source of these multi-trillion-dollar valuations.
• The "Innovation" Argument: Brian argued that even if these companies are overvalued, they represent the "final frontier" of American innovation. He emphasized that having a $20–$28 trillion addressable market in space and AI is preferable to an economy that lacks such risk-taking.
• Public Accountability: A key point raised is that going public forces these companies to be transparent about their financials and long-term viability, moving them from "hobby" projects to accountable public entities.

4. Healthcare Innovation: Eli Lilly and GLP-1s

The conversation shifted to the medical sector, specifically Eli Lilly’s next-generation obesity drug.

• Clinical Data: Phase III data indicates that patients lost an average of 28% of their body weight over 80 weeks. Half of the participants lost 30%, which the panel noted is comparable to the results of invasive bariatric surgery.
• Economic/Social Implications:
  • Cost Savings: Dagen argued that these drugs could significantly lower healthcare costs related to diabetes, potentially saving Medicare billions.
  • Lifestyle vs. Medication: The panel debated the ethics of relying on medication versus lifestyle changes, noting that these drugs may need to be taken for life to prevent weight regain.

Synthesis and Conclusion

The overarching theme is the rapid acceleration of American innovation in two distinct sectors: high-tech (AI/Space) and biotechnology. While the panel expressed caution regarding the "frothy" valuations of AI companies like OpenAI and Anthropic, they agreed that these firms are fundamentally changing the global economic landscape. Simultaneously, the medical breakthrough from Eli Lilly represents a shift in how society manages chronic health issues, potentially replacing surgical interventions with pharmaceutical solutions. The consensus is that while these investments carry high risks for retail participants, they are essential drivers of national competitiveness and economic growth.